Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 1/20 | 0.41 |
| ▸ | KDM5A | P29375 | 15/20 | 0.34 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | KDM5B | Q9UGL1 | 2/20 | 0.33 |
| ▸ | KDM5C | P41229 | 1/20 | 0.32 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29584063 | 1.00 | PTGES (0.41) | PTGESKDM5AGABRA1MEN1ALDH1A1 | |
| SCHEMBL29585623 | 1.00 | PTGES (0.41) | PTGESKDM5AGABRA1MEN1ALDH1A1 | |
| SCHEMBL29583451 | 1.00 | PTGES (0.41) | PTGESKDM5AGABRA1MEN1ALDH1A1 | |
| SCHEMBL24424711 | 1.00 | PTGES (0.41) | PTGESKDM5AGABRA1MEN1ALDH1A1 | |
| SCHEMBL29585145 | 0.92 | PTGES (0.40) | PTGESKDM5AMEN1ALDH1A1KMT2A | |
| SCHEMBL25090917 | 0.92 | PTGES (0.40) | PTGESKDM5AMEN1ALDH1A1KMT2A | |
| SCHEMBL25090918 | 0.92 | PTGES (0.40) | PTGESKDM5AMEN1ALDH1A1KMT2A | |
| SCHEMBL29585587 | 0.92 | PTGES (0.40) | PTGESKDM5AMEN1ALDH1A1KMT2A | |
| SCHEMBL24423010 | 0.91 | PTGES (0.39) | PTGESKDM5AGABRA1MEN1ALDH1A1 | |
| SCHEMBL24424350 | 0.91 | PTGES (0.39) | PTGESKDM5AGABRA1MEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230062861-A1 | PPARg MODULATORS AND METHODS OF USE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2023-03-02 | — | — | US | disclosed |
| WO-2022099144-A1 | ΡΡΑRγ MODULATORS AND METHODS OF USE | Eisai R&D Mangement Co., Ltd. (JP) | 2022-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230062861-A1 | PPARg MODULATORS AND METHODS OF USE | PPARG, PPARA, PPARD | PTGES 253/4885KDM5A 4027/4885GABRA1 478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.